The State of the Art in Chronic Prurigo Nodularis
Esther Serra-Baldrich, Ángeles Flórez, Marc Julià Manresa, Francisco Javier Ortiz de Frutos, José-Juan Pereyra-Rodriguez, Bibiana Pérez, Ignasi Figueras · 2026
Read The State of the Art in Chronic Prurigo Nodularis by Esther Serra-Baldrich, Ángeles Flórez, Marc Julià Manresa, Francisco Javier Ortiz de Frutos, José-Juan Pereyra-Rodriguez, Bibiana Pérez, Ignasi Figueras (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13280267.txt.
Description
Esther Serra-Baldrich and colleagues published a 2026 narrative review of chronic prurigo nodularis, a skin disease of intensely itchy nodules that can persist for years and damage quality of life. The condition mostly affects older women and travels with other skin, psychiatric, and metabolic diseases. Its engine is a self-feeding itch-scratch cycle. Type-2 immune signals, nerve peptides, and scarring pathways reinforce one another in what the authors call a neuro-immune-fibrotic axis.
The disease's definition and name remain contested, with European and American guidance documents diverging. Treatment is shifting from improvised off-label drugs toward targeted biologics. Dupilumab and nemolizumab are the only agents backed by phase III trial evidence. JAK inhibitors look promising but remain investigational and need careful safety framing. The authors catalogue what is settled about causes and epidemiology. They press for standardized guidelines and treat-to-target strategies tuned to patients.
Catalog record
| CREATOR | Esther Serra-Baldrich, Ángeles Flórez, Marc Julià Manresa, Francisco Javier Ortiz de Frutos, José-Juan Pereyra-Rodriguez, Bibiana Pérez, Ignasi Figueras |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |